Leading the Way in Humoral Immuno-Oncology

At Navrogen, our team of experts is striving to provide innovative solutions to overcome immunosuppressive mechanisms at play in the Humoral Immuno-Oncology space.

Publications   Pipeline

Visit us at AACR 2024
Poster Sessions
April 8, 9:00 am
April 9, 1:30 pm


Translating Clinical Knowledge Into Innovation

Our mission is to develop therapeutic agents that can overcome the immunosuppressive effects of factors that suppress humoral immune responses produced by tumors as well as develop diagnostic tools that can identify these factors in patients’ tumors to guide physicians on new therapeutic options

Navrogen is pursuing a novel approach by targeting immunosuppressive pathways affecting humoral immunity.

Dr. Jeffrey V. Ravetch

Navrogen’s discovery of HIO factors will help us understand how tumors evade humoral immunity

Dr. Manish Patankar

News & Events

Us Nih Nci Logo
Levena Logo